Clinical Trials Browser

Completed × Waldenstrom Macroglobulinemia × daratumumab × Clear all

NCT03187262 2022-11-23

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Phase 2 Completed

13 enrolled 11 charts

Waldenstrom Macroglobulinemia